|
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Pfizer; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen |
|
|
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - EUSA Pharma; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - BMSi; Eisai; Novartis |
Consulting or Advisory Role - Pfizer |
|
|
Travel, Accommodations, Expenses - EUSA Pharma; Novartis; Pfizer |